BioSpace News Archive

FDA

Novo Nordisk Snags FDA Approval for Oral Type 2 Diabetes Drug

Novo Nordisk’s oral-semaglutide for type 2 diabetes snagged approval from the U.S. Food and Drug Administration late Friday, marking it as the first such treatment to be approved in pill form.

September 23, 2019
·
2 min read
·
Alex Keown
Business

GSK’s Emma Walmsley to Bring Biopharma and Healthcare Expertise to Microsoft Board of Directors

Microsoft announced that Emma Walmsley, chief executive officer of GlaxoSmithKline, had been nominated to the company’s board of directors.

September 23, 2019
·
3 min read
·
Mark Terry
Genetown

On the Cusp of the Epigenetics Frontier: Constellation Pharmaceuticals

Constellation Pharma’s president and chief executive officer, Jigar Raythatha, took time out to speak with BioSpace about the company and where it’s headed with the field of epigenetics.

September 23, 2019
·
5 min read
·
Mark Terry
Business

Omega Therapeutics Debuts to Develop Epigenetic Drugs

Epigenetics is the study of changes in gene expression that don’t involve changes to the DNA sequence.

September 23, 2019
·
3 min read
·
Mark Terry
Business

Akcea Sees Abrupt Departure of Three Senior Executives

As Akcea Therapeutics moves forward with a second attempt to gain regulatory approval for Waylivra, it will do so without a number of its C-suite executives.

September 23, 2019
·
3 min read
·
Alex Keown
Genetown

MtoZ Biolabs Developed Protein De Novo Sequencing Service

MtoZ Biolabs, a start-up biotech company specialized in quantitative proteomics and metabolomics services, developed protein de novo sequencing platform to assist researchers’ study in Proteomics.

September 23, 2019
·
4 min read
Drug Development

Ipsen’s Dysport Effective in Treating Limb Spasticity

Ipsen announced positive data from the ENGAGE Phase IIIb/IV clinical trial of Dysport (abobotulinumtoxinA) to treat upper and lower limb spasticity in adults with a Guided Self-rehabilitation Contract.

September 23, 2019
·
2 min read
·
Mark Terry
Business

Clovis Moves into Radiopharmaceuticals Through $12 Million Deal with 3B

Clovis Oncology plunked down $12 million in an upfront payment to Germany-based 3B Pharmaceuticals for licensing rights to peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein alpha.

September 23, 2019
·
2 min read
·
Alex Keown
Your Feedback Matters! Career Path Direction

As a valued member of our BioSpace community, we are eager to hear more from you and other readers in 2019. We want to know your career path direction you took or plan to take.

September 23, 2019
·
1 min read
·
BioSpace Staff
ACD/Labs Releases v2019 Software Updates to its Spectrus and Percepta Platform Applications

Software enhancements offer a complete application for CMC decision support, improvements for analytical data processing and analysis, and a move to 64-bit architecture.

September 23, 2019
·
3 min read